Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kemira Oyj sells pharmaceutical business to Niacet
The businesses form part of Kemira’s ChemSolutions segment, according to Kemira Oyj. As part of the agreement, the shares of Kemira ChemSolutions, the manufacturing site in Tiel, Netherlands
The businesses form part of Kemira’s ChemSolutions segment, according to Kemira Oyj. As part of the agreement, the shares of Kemira ChemSolutions, the manufacturing site in Tiel, Netherlands
The company’s loading dose formulation of fusidic acid, CEM-102, has an established history of safety and efficacy outside the US. Open-label trial will randomize 50 PJIs patients with
The kit is built by combining the Gibson Assembly Master Mix along with NEB 5-alpha competent E. coli, enabling fragment assembly and cloning in less than two hours.
The center will combine molecular and cell biologists to provide them with genomics and genotypic data for assessment of biological pathways, disease mechanisms and the characterization of healthy
The deal, which is anticipated to complete in January 2013, is subject to certain closing conditions. Bio-Rad life science group president Brad Crutchfield said, "With this acquisition, Bio-Rad
The activities of Teva-Handok business venture are anticipated to begin in few months subsequent to the issuance of approvals by the regulatory bodies. Teva South Korea chairman, business
Efficacy of the monoclonal anti-toxin medication against inhalational anthrax, caused due to Bacillus anthracis, was established in studies conducted in animal models while the safety profile was demonstrated
The only approved pituitary-directed therapy in the US, for the patients who are not suitable for pituitary surgery, addresses the principal mechanism of Cushing’s disease. Novartis Oncology president
The antisense drug ISIS-TTR, a part of the Isis-GSK strategic RNA therapeutic alliance, is being developed for the treatment of transthyretin (TTR) amyloidosis. TTR amyloidosis is a severe
Viread is indicated for HIV-1 infected children between two to six years of age and for HIV-1 infected children more than six years for whom solid dosage is